NCT03375242 - Safety and Efficacy of Xalkori ROS1 | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

March 26, 2027

Study Completion Date

March 26, 2027

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

crizotinib

"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows. The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "

Trial Locations (1)

Unknown

RECRUITING

Pfizer Tokyo, Tokyo